|Bid||335.50 x 255900|
|Ask||336.40 x 42900|
|Day's Range||328.10 - 335.90|
|52 Week Range||2.87 - 364.00|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
BioLineRx (BLRX) posts encouraging partial results from the monotherapy portion of a phase IIa COMBAT study, assessing its lead pipeline candidate, BL-8040, for pancreatic cancer patients.
Bioline RX Ltd (NASDAQ:BLRX) is officially turning its Phase 3 GENESES clinical trial's wheels, with the Israeli drug maker revealing today the launch of evaluating its stem-cell mobilization asset BL-8040. In the initiation of the clinical trial, BiolineRx will be investigating the mobilization of hematopoietic stem cells by BL-8040 against a placebo, on top of granulocyte colony-stimulating factor (G-CSF), a powerful inducer of hematopoietic stem cell (HSC) mobilization from the bone marrow into the bloodstream.
BioLineRx (BLRX) and partner Genentech initiate a phase Ib/II study to evaluate the company's lead pipeline candidate, BL-8040, in combination with Tecentriq for treating gastric cancer.
BioLineRx (BLRX) forwards a regulatory submission to begin a phase III study to evaluate BL-8040 in combination with G-CSF for treatment of multiple myeloma.
BioLineRx Ltd. (BLRX) announced that its partner Genentech, has initiated a phase Ib/II study, evaluating BL-8040 in combination Tecentriq (atezolizumab) for treatment of patients with metastatic pancreatic ductal adenocarcinoma.
BioLineRx Ltd. (BLRX) announced that it has submitted a regulatory filing required to start a phase Ib study for BL-8040 in combination with Roche Group's (RHHBY) Tecentriq (atezolizumab).